Study of Etoposide in Treating Patients With Recurrent or Metastatic Breast Cancer
A Phase II, Single-arm, Multicenter Study of Etoposide Monotherapy in Treating Patients With Recurrent or Metastatic Breast Cancer
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Peng Yuan, M.D.
- Phone Number: 86-10-8778-8114
- Email: yuanpeng01@hotmail.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100142
- Recruiting
- Peking University Cancer Hospital
-
Contact:
- Ying Yan, MD
- Phone Number: +86-13141316976
- Email: yan99640815@yahoo.com.cn
-
Sub-Investigator:
- Ying Yan, MD
-
Beijing, Beijing, China, 100005
- Recruiting
- Peking Union Medical College Hospital
-
Contact:
- Changjun Wang, MD
- Phone Number: +86-10-6915-8936
- Email: wangchangjun.cannei@gmail.com
-
Principal Investigator:
- Qiang Sun, MD
-
Sub-Investigator:
- Changjun Wang, MD
-
Beijing, Beijing, China, 100029
- Recruiting
- China-Japan Friendship Hospital
-
Sub-Investigator:
- Donggui Wan, MD
-
Beijing, Beijing, China, 100021
- Recruiting
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
-
Contact:
- Peng Yuan, M.D.
- Phone Number: 86-10-8778-8114
- Email: yuanpeng01@hotmail.com
-
Principal Investigator:
- Binghe Xu, M.D., Ph.D
-
Beijing, Beijing, China, 100020
- Recruiting
- Beijing Chao-Yang Hospital
-
Principal Investigator:
- Guangyu An, MD
-
Beijing, Beijing, China, 100005
- Recruiting
- Beijing Hospital of the Ministry of Health
-
Contact:
- Li Ding, MD
- Phone Number: +86-13701314630
- Email: zhangygqg@yahoo.com.cn
-
Principal Investigator:
- Yongqiang Zhang, MD
-
Sub-Investigator:
- Li Ding, MD
-
-
Guangxi
-
Nanning, Guangxi, China, 530021
- Recruiting
- Guangxi Cancer Hospital
-
Contact:
- Hongxue Wang, MD
- Phone Number: +86-13978806626
-
Principal Investigator:
- Wei Wei, MD
-
Sub-Investigator:
- Hongxue Wang, MD
-
-
Heilongjiang
-
Harbin, Heilongjiang, China, 150081
- Recruiting
- Harbin Medical University Cancer Hospital
-
Principal Investigator:
- Qingyuan Zhang, MD
-
Contact:
- Qingyuan Zhang, MD
- Phone Number: 86-451-86298800
-
-
Henan
-
Zhengzhou, Henan, China, 450008
- Recruiting
- Henan Cancer Hospital
-
Contact:
- Min Yan, MD
- Phone Number: +86-13673641112
- Email: ym200678@126.com
-
Principal Investigator:
- Shujun Yang, MD
-
Sub-Investigator:
- Min Yan, MD
-
-
Liaoning
-
Dalian, Liaoning, China, 116011
- Recruiting
- First Affiliated Hospital of Dalian Medical University
-
Contact:
- Weiwei Gong, MD
- Phone Number: +86-18941197930
- Email: gongweiwei12@163.com
-
Sub-Investigator:
- Weiwei Gong, MD
-
-
Shanghai
-
Shanghai, Shanghai, China, 200030
- Recruiting
- International Peace Maternity & Child Health Hospital Of The China Welfare Institute
-
Contact:
- Qi He, MD
- Phone Number: +86-13801858957
-
Principal Investigator:
- Qi He, MD
-
Shanghai, Shanghai, China, 200062
- Recruiting
- Shanghai Putuo District Center Hospital
-
Contact:
- Qi Zhu, MD
- Phone Number: +86-13301679760
-
Principal Investigator:
- Miaoqian Liang, MD
-
Sub-Investigator:
- Qi Zhu, MD
-
-
Xinjiang
-
Urumqi, Xinjiang, China, 830011
- Recruiting
- Affiliated Cancer Hospital of Xinjiang Medical University
-
Contact:
- Duo Ni, MD
- Phone Number: +86-13909926820
-
Principal Investigator:
- Duo Ni, MD
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310022
- Recruiting
- Zhejiang Cancer Hospital
-
Contact:
- Jufen Cai, MD
- Phone Number: +86-13867168680
- Email: CaiJf108@126.com
-
Principal Investigator:
- Jufen Cai, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age: 18-80 years old.
- ECOG status: 0-2.
- Histologic or cytologic diagnosis of locally advanced or metastatic breast cancer.
- No more than three prior chemotherapies, adjuvant chemotherapy excluded.
- Received prior anthracycline, taxane therapy.
- At least 4 weeks from previous chemotherapy.
- Measurable disease of >=2 cm (>=1 cm on spiral CT scan).
- Life expectancy of ≥ 3 months.
Adequate organ functions:
- Hemoglobin ≥10.0 g/dl, Absolute neutrophil count ≥1.5×10^9/L, Platelet count ≥100×10^9/L,
- Creatinine clearance ≥60ml/min,
- Bilirubin ≤1.5 times upper limit of normal (ULN); AKP,AST and ALT ≤2.5x ULN(≤5x ULN if due to liver metastases).
- Signed informed consent.
- Menopausal women or received surgical sterilization, women with children potential must not be pregnant or nursing with negative pregnancy test and willing to practice acceptable methods of birth control during the study and 3 months after the study.
Exclusion Criteria:
- Pregnancy or lactation.
- Untreated or uncontrolled CNS metastases, or with refractory psychiatric illness.
- Prior treatment with Etoposide.
- Other primary malignancies within the past 5 years except for carcinoma in situ of the cervix or nonmelanoma skin cancer.
- Clinically significant heart diseases (e.g.congestive heart failure, symptomatic coronary disease, uncontrolled cardiac arrhythmia, Myocardial infarction) within the past 12 months.
- Serious uncontrolled concurrent infection or metabolism disorder.
- Concurrent treatment for active peptic ulcer disease or with digestive disorders.
- Prior radiotherapy and major surgery within 3 weeks before screening.
- Less than 4 weeks since prior investigational agents.
- Metastases present in more than one-third whole liver.
- Unable or unwilling to comply with the study protocol.
- Unsuitable to participate in study, that in the opinion of the treating physician.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: Etoposide
Etoposide Capsules
|
Lastet (Etoposide Capsules, 25mg*40 capsules/box), manufactured by Nippon Kayaku Co., Ltd.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Progression-free survival
Time Frame: Up to 1 year
|
Up to 1 year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Clinical response rate
Time Frame: Every six weeks
|
Assessed by RECIST v1.1 criteria.
|
Every six weeks
|
|
1-year survival rate
Time Frame: Up to 1 year
|
Up to 1 year
|
|
|
Adverse events
Time Frame: Subjects will be followed from date of enrollment until the date of last visit, expected up to 1 year
|
Subjects will be followed from date of enrollment until the date of last visit, expected up to 1 year
|
|
|
Quality of Life
Time Frame: Every six weeks
|
Every six weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Binghe Xu, M.D., Ph.D, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ANTICIPATED)
Primary Completion
Study Completion (ANTICIPATED)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CH-BC-015
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.